Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on September 30, 2025, Edgewise granted inducement stock options to purchase a total of 247,000 shares of Edgewise's common stock and awards of inducement restricted stock units ("RSU awards") covering a total of 15,000 shares of Edgewise's common stock to 9 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Read more at prnewswire.com